Oral Semaglutide
Sources
fda, as of 2026-05-05Stale
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/215256Orig1s031.pdf
Sponsor: Novo Nordisk Inc. Trade Name: WEGOVY. Generic or Proper Name: semaglutide. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity. WEGOVY tablets are indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity.
Approval package 215256Orig1s031, highlights and Table 8 Study 2 and Table 12 Study 8
registry, as of 2026-05-07Stale
https://clinicaltrials.gov/study/NCT05035095
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1). Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 667. Conditions Obesity; Overweight. This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or Percentage Change in Body Weight Oral Semaglutide 50 mg -15.8 Percentage (%) change in body weight Baseline (week 0), end-of-treatment (week 68) Percentage Change in Body Weight Placebo -2.2 Percentage (%) change in body weight Baseline (week 0), end-of-treatment (week 68) Change in Glycosylated Haemoglobin (HbA1c) Oral Semaglutide 50 mg -0.2 Percentage
ClinicalTrials.gov NCT05035095 protocol and results modules
registry, as of 2026-09-09Stale
https://clinicaltrials.gov/study/NCT07770841
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 450. Conditions Overweight; Obesity. The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semagl
ClinicalTrials.gov NCT07770841 protocol and results modules
registry, as of 2026-02-25Stale
https://clinicaltrials.gov/study/NCT05564117
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 307. Conditions Overweight; Obesity. This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screenin Percentage Change in Body Weight Oral Semaglutide 25 mg -14.4 Percentage change in body weight Baseline (week 0), end of treatment (week 64) Percentage Change in Body Weight Placebo -2.5 Percentage change in body weight Baseline (week 0), end of treatment (week 64) Change in Glycosylated Haemoglobin (HbA1c) Oral Semaglutide 25 mg -0.3 Percentage of HbA1c Change
ClinicalTrials.gov NCT05564117 protocol and results modules
registry, as of 2026-08-14Stale
https://clinicaltrials.gov/study/NCT05132088
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 201. Conditions Overweight and Obesity. Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight. Participants will either get semaglutide tablets (new medicin Percent Change From Baseline in Body Weight Oral Semaglutide 50 mg -14.9 Percent change of body weight Baseline (week 0), week 68 Percent Change From Baseline in Body Weight Oral Semaglutide Placebo -1.5 Percent change of body weight Baseline (week 0), week 68 Change From Baseline in Glycosylated Haemoglobin (HbA1c) Oral Semaglutide 50 mg -0.8 Change
ClinicalTrials.gov NCT05132088 protocol and results modules
registry, as of 2026-01-22Stale
https://clinicaltrials.gov/study/NCT05890976
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3). Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 200. Conditions Overweight; Obesity. This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either
ClinicalTrials.gov NCT05890976 protocol and results modules